Submit the keyword or topic you are searching for

  1. Home
  2. Health
  3. NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance
Health

NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance

featured-image

NeuroPace ( NASDAQ: NPCE ) announced that it is refocusing its product portfolio on its core, differentiated RNS System product line. As part of this strategic shift, NPCE will terminate its distribution relationship for SEEG products, beginning in Q4, 2025 and continuing through Q1, 2026..

My Protein Germany

Myprotein UK

Menkind UK

Top News

Delhi Fast-Tracks Infrastructure with High-Level Committee

Delhi Fast-Tracks Infrastructure with High-Level Committee A...

Pedaling for Justice: Serbian Students Ride for EU Support

Political Unrest: SDPI Protest Sparks Controversy

DR Congo: Millions Facing Destitution as Violence Forces People to Flee Multiple Times

Related Posts

post-thumbnail
Health

Millions of Afghans lose access to healthcare services as USAID cuts shut clinics

post-thumbnail
Health

Nobel Laureate, Prestigious Award Recipients to Speak at American Physiology Summit

post-thumbnail
Health

TB response under strain

post-thumbnail
Health

Hay fever sufferers spend more than £3,600 on medication over their lifetime

post-thumbnail
Health

Lindus Health Awarded Funding from ARIA to Build Safe and Reliable AI for Clinical Trial Design

post-thumbnail
Health

Amid Surgeon General's Warning on Alcohol and Cancer, Middle-Aged Women Rethink Drinking

post-thumbnail
Health

AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray

post-thumbnail
Health

Ryght AI Welcomes the Medical College of Wisconsin to Global Site Network As Their Latest Academic Partner